Flu Vaccine Panel Meeting Canceled, Us Fda Confirms
The U.S. Food and Drug Administration confirmed on Thursday that a meeting of its independent advisory panel to discuss the composition of this year's flu vaccine had been canceled and that the regulator would instead make recommendations later. The agency had scheduled the meeting for March 13 but cited unspecified reasons for its cancellation. By postponing the meeting, the FDA may be able to gather more public comment on its proposed vaccine.
- This delay highlights the complex and often contentious process of vaccine development, where scientific experts must navigate conflicting interests and public scrutiny.
- What role will the Biden administration's efforts to increase vaccine accessibility play in shaping the composition of this year's flu vaccine?